RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS SCIE

      Physicochemical and antibacterial characterization of Aspergillus sp. filtrate-reduced graphene oxide

      한글로보기

      https://www.riss.kr/link?id=A108013065

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Graphene-based nanomaterials are rapidly emerging as antimicrobial agents against a range of pathogenicmicroorganisms. In the present study, we have demonstrated the synthesis of reduced grapheneoxide (RGO) using Aspergillus sp. filtrate as a reducing agent. The obtained Aspergillus sp. filtrate-RGO(AF-RGO) was characterized by ultraviolet–visible absorption spectroscopy, dynamic light scattering,X-ray diffraction, Fourier-transform infrared spectroscopy, Raman spectroscopy, scanning electronmicroscopy, transmission electron microscopy, X-ray photoelectron spectroscopy, and atomic force spectroscopyto obtain details about the size, composition, structure, and morphology. The characterizationconfirmed the reduction of graphene oxide, the restoration of sp2 conjugation, and the formation offew-layered RGO sheets. The surface charge and stability of the AF-RGO in aqueous media were examinedby zeta potential measurements. The thermal stability of AF-RGO was increased significantly due to therestoration of the graphitic sp2 network. The antibacterial activity of AF-RGO was evaluated using theagar well diffusion method, broth microdilution method, and Live/Dead bacterial viability assay. AFRGOexhibited good antibacterial activities against pathogenic Gram-negative (Escherichia coli) andGram-positive (Staphylococcus aureus) bacteria with minimum inhibitory concentration (MIC) and minimumbactericidal concentration (MBC) values of 15 and 30 mg/ml, respectively. Therefore, fungal filtratemediatedsynthesis of RGO is a promising antibacterial carbon nanomaterial for a range of biomedical andnano(bio)technological applications.
      번역하기

      Graphene-based nanomaterials are rapidly emerging as antimicrobial agents against a range of pathogenicmicroorganisms. In the present study, we have demonstrated the synthesis of reduced grapheneoxide (RGO) using Aspergillus sp. filtrate as a reducing...

      Graphene-based nanomaterials are rapidly emerging as antimicrobial agents against a range of pathogenicmicroorganisms. In the present study, we have demonstrated the synthesis of reduced grapheneoxide (RGO) using Aspergillus sp. filtrate as a reducing agent. The obtained Aspergillus sp. filtrate-RGO(AF-RGO) was characterized by ultraviolet–visible absorption spectroscopy, dynamic light scattering,X-ray diffraction, Fourier-transform infrared spectroscopy, Raman spectroscopy, scanning electronmicroscopy, transmission electron microscopy, X-ray photoelectron spectroscopy, and atomic force spectroscopyto obtain details about the size, composition, structure, and morphology. The characterizationconfirmed the reduction of graphene oxide, the restoration of sp2 conjugation, and the formation offew-layered RGO sheets. The surface charge and stability of the AF-RGO in aqueous media were examinedby zeta potential measurements. The thermal stability of AF-RGO was increased significantly due to therestoration of the graphitic sp2 network. The antibacterial activity of AF-RGO was evaluated using theagar well diffusion method, broth microdilution method, and Live/Dead bacterial viability assay. AFRGOexhibited good antibacterial activities against pathogenic Gram-negative (Escherichia coli) andGram-positive (Staphylococcus aureus) bacteria with minimum inhibitory concentration (MIC) and minimumbactericidal concentration (MBC) values of 15 and 30 mg/ml, respectively. Therefore, fungal filtratemediatedsynthesis of RGO is a promising antibacterial carbon nanomaterial for a range of biomedical andnano(bio)technological applications.

      더보기

      참고문헌 (Reference)

      1 M. Hu, 47 : 6233-, 2018

      2 K. B. Narayanan, 191 : 2020

      3 R. J. Price, 56 : 466-, 2019

      4 B. Gurunlu, 2020 : 7029601-, 2020

      5 W. S. Hummers, 80 : 1339-, 1958

      6 M. C. Kim, 131 : 2009

      7 G. Wang, 4 : 563-, 2011

      8 O. Akhavan, 50 : 1853-, 2012

      9 P. Khanra, 183 : 526-, 2012

      10 K. B. Narayanan, 181 : 539-, 2019

      1 M. Hu, 47 : 6233-, 2018

      2 K. B. Narayanan, 191 : 2020

      3 R. J. Price, 56 : 466-, 2019

      4 B. Gurunlu, 2020 : 7029601-, 2020

      5 W. S. Hummers, 80 : 1339-, 1958

      6 M. C. Kim, 131 : 2009

      7 G. Wang, 4 : 563-, 2011

      8 O. Akhavan, 50 : 1853-, 2012

      9 P. Khanra, 183 : 526-, 2012

      10 K. B. Narayanan, 181 : 539-, 2019

      11 S. Gurunathan, 8 : 393-, 2013

      12 K. Lingaraju, 24 : 2019

      13 K. B. Narayanan, 185 : 2020

      14 X. F. Zhang, 11 : 6635-, 2016

      15 C. Zhu, 4 : 2429-, 2010

      16 L. Cao, 6 : 35184-, 2016

      17 J. Wang, 72 : 1-, 2017

      18 Y. Shen, 72 : 1430-, 2012

      19 S. J. Park, 22 : 1-, 2010

      20 D. Mhamane, 22 : 11140-, 2012

      21 S. Liu, 5 : 6971-, 2011

      22 Z. Yang, 533 : 13-, 2019

      23 J. Ma, 21 : 3350-, 2011

      24 S. Gurunathan, 9 : 1783-, 2014

      25 S. Gurunathan, 7 : 5901-, 2012

      26 O. Akhavan, 22 : 13773-, 2012

      27 H. Barabadi, 45 : 1493-, 2014

      28 V. S. Sapner, 8 : 5524-, 2020

      29 L. Cai, 40 : 2925-, 2017

      30 D. Li, 3 : 101-, 2008

      31 S. B. Maddinedi, 126 : 227-, 2014

      32 K. Muthoosamy, 10 : 1505-, 2015

      33 D. Hou, 4 : 256-, 2018

      34 D. R. Dreyer, 39 : 228-, 2009

      35 H. M. Ju, 64 : 357-, 2010

      36 A. Barth, 1767 : 1073-, 2007

      37 J. L. Bahr, 12 : 1952-, 2002

      38 K. B. Narayanan, 160 : 90-, 2017

      39 I. Roy, 6 : 10557-, 2016

      40 X. Zheng, 5 : 2015

      41 A. Dato, 8 : 2012-, 2008

      42 G. M. Bhalerao, 41 : 54-, 2008

      43 A. Esfandiar, 21 : 10907-, 2011

      44 B. Gupta, 7 : 45030-, 2017

      45 G. M. Bhalerao, 86 : 2012

      46 I. Calizo, 7 : 2645-, 2007

      47 L. Liu, 8 : 1965-, 2008

      48 K. S. Kim, 457 : 706-, 2009

      49 O. Akhavan, 81 : 158-, 2015

      50 N. B. Schorr, 90 : 7848-, 2018

      51 S. Thakur, 50 : 5331-, 2012

      52 S. Priyadarsini, 8 : 123-, 2018

      53 S. Park, 49 : 3019-, 2011

      54 O. Akhavan, 48 : 509-, 2010

      55 S. Vahabi, 38 : 76-, 2013

      56 J. F. Dai, 40 : 60-, 2015

      57 H. B. Zhang, 21 : 5392-, 2011

      58 A. A. Al-Fakih, 10 : 191-, 2019

      59 J. W. Bok, 13 : 31-, 2006

      60 A. A. P. Bracarense, 45 : 313-, 2014

      61 P. Choudhary, 4 : 387-, 2019

      62 Y. Inamori, 31 : 4543-, 1983

      63 W. Xu, 34 : 103-, 2015

      64 O. Akhavan, 4 : 5731-, 2010

      65 H. Mohammed, 8 : 465-, 2020

      66 O. Akhavan, 115 : 6279-, 2011

      67 M. N. Rani, 4 : 12300-, 2017

      68 J. Robertson, 10 : 801-, 2019

      69 H. Rudilla, 4 : 522-, 2018

      70 D. Sfyris, "arXiv:1706.04465"

      71 CLSI (Clinical and Laboratory Standards Institute), "Approved Standard, M07-A8" 2011

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2011-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2009-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2007-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2004-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2003-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2001-07-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 3.4 0.75 2.84
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      2.39 2.24 0.397 0.56
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼